Jury orders Gilead to pay Merck $2.5bn in patent case

December 16, 2016

A US jury has ordered pharmaceutical giant Gilead Sciences to pay $2.5 billion to competitor Merck in a patent infringement case involving a drug used to treat hepatitis C, the two companies said.

A in Delaware on Thursday sided with Merck subsidiary Idenix, which claimed that Gilead's blockbuster sofosbuvir drug and its derivatives, sold under the labels Solvadi et Harvoni, violated one of its patents.

"The patent at issue in this case facilitated significant advances in the treatment of patients with HCV infection and was appropriately granted," Merck said in a statement.

"Achieving these advancements required many years of research and significant investment by our subsidiary and its partners," it added.

Gilead announced plans to appeal the ruling, and said the decision would not affect its ability to supply the drug to US patients.

Sofosbuvir came under the Gilead portfolio in 2011, when the biotech company acquired Pharmasset, which held the drug's patent.

Hepatitis C, a blood-borne viral disease, affects 130 to 150 million people globally and can result in or cancer.

According to the World Health Organization, it is responsible for 700,000 deaths yearly.

Explore further: Jury: Gilead owes Merck $200M in damages over drug patents (Update)

Related Stories

Charity scores small win in Hep C drug battle

October 5, 2016

A medical charity scored a small victory Wednesday in its bid to break a US pharma giant's hold on an eye-wateringly expensive Hepatitis C drug when a European body partially revoked the firm's patent.

Gilead wins India patent for blockbuster Hepatitis drug

May 10, 2016

India has granted a patent to US pharmaceutical giant Gilead for a blockbuster Hepatitis C drug, in a U-turn activists said could potentially stop affordable copies reaching millions of people in other countries.

US group seeks to block Gilead drug patent in India

November 24, 2013

A US-based patient rights group said Saturday it has sought to block a bid by California-based Gilead Sciences to obtain an Indian patent for a potentially blockbuster drug to treat hepatitis C.

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.